Related stories
Pfizer raises full-year outlook on strong anticoagulant, cancer drug sales
Pfizer raised its full-year outlook. The supplied report says anticoagulant and cancer drug performance was strong.
M impact | EARNINGS | Nov 04, 2026, 01:28 AM UTC
HYTC Third-Quarter Revenue Rises 48.5% Year Over Year
HYTC's preliminary consolidated third-quarter 2026 revenue increased 48.5% year over year.
M impact | EARNINGS | Nov 04, 2026, 01:25 AM UTC
BrasilAgro Cuts 2026/27 Grain and Cotton Production Forecast by 3%
BrasilAgro lowered its forecast for grain and cotton production in the 2026/27 season by 3%.
L impact | EARNINGS | Nov 04, 2026, 01:12 AM UTC
Itaú Unibanco Reports R$12.6 Billion Recurring Result for 3Q26
The recurring managerial result rose 6.2% year over year, while return on equity was 23.6%. Client margin grew 6.6%, partly offset by a 10.2% increase in the cost of credit. Itaú l
M impact | EARNINGS | Nov 04, 2026, 01:03 AM UTC
Suncor Energy Reports Results for Quarter Ended September 30
L impact | EARNINGS | Nov 04, 2026, 01:01 AM UTC
SK Telecom Operating Profit Rises 1,040.3%
SK Telecom reported consolidated operating profit for Q3 2026, up 1,040.3% year over year.
M impact | EARNINGS | Nov 04, 2026, 12:54 AM UTC